Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ProfoundBio Provides Updates on Two ADC Candidates in US-China Trials

publication date: May 26, 2023

ProfoundBio, a Suzhou-Seattle ADC biotech, has dosed the first patients in a US Phase I/II trial of its CD70 ADC, PRO1160, and it was approved to start a similar trial in China. The company was also approved to start a Phase I/II trial of Rina-S in China. Rina-S, which will be tested in patients with solid tumors or mesothelioma, has already shown promising results in a US trial. Both candidates use ProfoundBio’s novel hydrophilic linker and exatecan payload that is designed to reduce off-target toxicities. More details.....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here